Journal of Immunotherapy · 2006 · 24 citations · 27 references
MedicineImmunologyOncologyCancer ImmunologyMolecular ImagingTumor ImmunologyCancer ImmunotherapyCell TrackingCellular TherapyT Cell Responses To TumorsTumor ImagingTumor-infiltrating LymphocytesCd8 Positive T CellsCd8+ Tumor-infiltrating LymphocytesCell HomingImmune Cell HomingPositron Emission Tomography DetectionT Cell Trafficking To TumorsT-cell RecruitmentTumor Tracking
A general hindrance to progress in adoptive cellular therapy is the lack of detailed knowledge of the fate of transferred cells in the body of the recipient. In this study, we present a novel technique for tracking of 124I-labeled cells in situ, which combines the high spatial resolution of magnetic resonance imaging with the high sensitivity and spatial accuracy of positron emission tomography. We have used this technique, together with determination of tissue radioactivity, flow cytometry, and microscopy, to characterize and quantitate the specific accumulation of transferred CD8+ T cells in tumor tissue in a mouse model. Transgenic CD8+ T cells, specific for the ovalbumin peptide SIINFEKL, were adoptively transferred to recipients carrying a subcutaneous tumor of the ovalbumin-expressing malignant melanoma cell line B16-OVA. The number of SIINFEKL-specific CD8+ cells in the tumor tissue was determined by flow cytometry each day for 8 consecutive days after adoptive transfer. From low levels 1 day after injection, their number gradually increased until day 5 when an average of 3.3x10(6) SIINFEKL-specific cells per gram tumor tissue was found. By applying the combined positron emission tomography/magnetic resonance imaging technique we were able to determine the position of the transferred, 124I-labeled SIINFEKL-specific T cells in 3 dimensions in recipient mice, and could demonstrate a highly significant accumulation of the 124I label in and around the subcutaneous B16-OVA tumors compared with normal tissue. Accumulation of 124I was significantly higher in B16-OVA than in B16 tumors not expressing the OVA antigen.
27
T cell receptor antagonist peptides induce positive selection
Kristin A. Hogquist, Stephen C. Jameson, William R. Heath et al. · Cell · 1994 · 2.9K citations
Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes
Mark E. Dudley, John R. Wunderlich, Paul F. Robbins et al. · Science · 2002 · 2.8K citations · Full text
Life Sciences, Immunology, Oncology +17
Cassian Yee, John A. Thompson, D. Byrd et al. · Proceedings of the National Academy of Sciences · 2002 · 1.2K citations
Medicine, Immunology, Oncology +17
Correction for partial volume effects in PET: principle and validation.
Olivier Rousset, Yilong Ma, Alan C. Evans · PubMed · 1998 · 934 citations
In vivo imaging platform for tracking immunotherapeutic cells
Eric T. Ahrens, Rafael R. Flores, Hongyan Xu et al. · Nature Biotechnology · 2005 · 614 citations
Medicine, Immunology, Oncology +14